UroGen's ZUSDURI more than doubles revenue in Q1 2026

UroGen Pharma has reported first-quarter 2026 revenues of $51.0 million, more than doubling the $20.3 million recorded in the same period a year earlier, as its flagship bladder-cancer product ZUSDURI rapidly built commercial momentum following its US approval.

ZUSDURI (mitomycin for intravesical solution), approved for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), generated net product revenue of $29.2 million in Q1 2026 — representing 109% quarter-on-quarter growth. The company attributes much of the acceleration to the introduction of a permanent Healthcare Common Procedure Coding System Level II J Code (J9282), which became effective on 1 January 2026 and substantially improved reimbursement clarity for both hospital and community urology settings.

As of 31 March 2026, UroGen reported 972 activated sites of care, 256 unique prescribers and 103 repeat prescribers — the last figure being particularly closely watched by investors as an indicator of sustained clinical uptake rather than trial-driven novelty.

Commercial and clinical context

Chief executive Liz Barrett described 2026 as "off to a strong start," citing growing clinical confidence in ZUSDURI as a non-surgical primary therapy and "early validation of our commercial model." The company did not provide full-year ZUSDURI revenue guidance, noting the product remains in the early stages of its commercial launch.

Updated data from the Phase 3 ENVISION trial, published ahead of print in the Journal of Urology, reported that patients achieving a complete response three months after first instillation had a 72.2% probability of remaining event-free at 24 months (95% CI: 64.1%–78.8%) on Kaplan-Meier analysis. These durability figures will be important to clinicians weighing ZUSDURI against the standard-of-care pathway of transurethral resection of bladder tumour (TURBT) followed by adjuvant chemotherapy.

Meanwhile, legacy product JELMYTO — approved for low-grade upper tract urothelial carcinoma (LG-UTUC) — contributed $21.7 million in the quarter, up approximately 7% year-on-year, and remains the more predictable revenue line. Full-year JELMYTO guidance is maintained at $97–101 million.

Pipeline and financial position

UroGen's net loss narrowed to $23.6 million ($0.47 per share) in Q1 2026 from $43.8 million ($0.92 per share) in Q1 2025, reflecting growing commercial revenues, though selling, general and administrative expenses climbed sharply to $51.5 million from $35.0 million — largely driven by the ZUSDURI sales force build-out and associated marketing spend.

To extend its financial runway, UroGen refinanced its debt facility with Pharmakon Advisors in February 2026, securing a $200 million first tranche to retire an existing $125 million facility and access additional non-dilutive capital, with a further $50 million optional tranche available until June 2027. Cash and marketable securities stood at $140.3 million at the quarter end.

The pipeline adds further optionality. UGN-103, a next-generation mitomycin formulation with a simplified manufacturing process, is on track for an NDA submission in the second half of 2026, supported by a 77.8% three-month complete response rate from the Phase 3 UTOPIA trial. Potential FDA approval is targeted for 2027. UGN-104, targeting LG-UTUC, is in a Phase 3 trial expected to complete enrolment by year-end. Most speculatively, UGN-501 — an investigational oncolytic virus for high-grade NMIBC — is approaching IND submission in Q2 2026, with a Phase 1 trial planned before year-end.

The non-muscle invasive bladder cancer market remains relatively underpenetrated by pharmaceutical products: TURBT has historically been the default intervention, and commercial uptake of instilled therapies has been constrained by reimbursement complexity and procedural inertia. The resolution of the J Code issue is structurally important for UroGen because it removes the most frequently cited barrier by urology practices considering ZUSDURI adoption. Whether repeat-prescriber numbers continue to compound at the current rate will be the key metric to watch in second-quarter results.